Say what you want about AstraZeneca’s castoff strategy, but it helped drive another earnings beat for the lacking-in-sales drugmaker to kick off the year.

Drugmakers have been salivating at the prospect of tax reform since President Donald Trump won the election. But some would benefit far more than others.…

Every quarter, the FiercePharma team analyzes biopharma earnings reports and investor calls, and we're compiling the first quarter's here. Check back…

What could China's newly proposed foreign drug policy mean for multinational pharma companies, and how will it change the world’s second-largest pharma…

Amgen and Sandoz faced off in oral arguments at the U.S. Supreme Court Wednesday in a case set to have a big impact on future biosim launches.

Another of Teva’s businesses could be up for grabs—and this time, it’s oncology, the company confirmed Wednesday.

If any GlaxoSmithKline investors were hoping new CEO Emma Walmsley would break with her predecessor and pursue a split-up, they got a rude awakening Wednesday.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth…

What would a migraine headache look like as art? That’s what Allergan is asking sufferers in a new campaign for chronic migraine awareness.

Pharma